An Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Combination With Sofosbuvir and Ribavirin in Chronic Hepatitis C (HCV) Infected Subjects Who Have Experienced Virologic Failure in AbbVie HCV Clinical Studies (MAGELLAN-3)
Phase of Trial: Phase III
Latest Information Update: 27 Feb 2018
At a glance
- Drugs Glecaprevir/pibrentasvir (Primary) ; Ribavirin; Sofosbuvir
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms MAGELLAN-3
- Sponsors AbbVie
- 06 Jan 2018 Planned number of patients changed from 40 to 50.
- 17 Jul 2017 Planned End Date changed from 10 Apr 2018 to 6 Sep 2019.
- 17 Jul 2017 Planned primary completion date changed from 5 Jan 2018 to 14 Jun 2019.